Diabetes drug may help to prolong preterm pregnancies in women with pre-eclampsia

Credit: CC0 Public Domain

Giving the drug metformin to women diagnosed with preterm pre-eclampsia may help to prolong pregnancy (gestation), finds a study published by The BMJ today.

The findings show that pregnancy was prolonged by a week in the treatment group compared with the no treatment group, but the result was not statistically significant and therefore points to the need for further study.

If confirmed by future research, this could have important benefits for both mother and baby.

Pre-eclampsia is a serious condition thought to be caused by the placenta not developing properly. Preterm (between 26-32 weeks’ gestation) often leads to early delivery, putting babies at risk of serious disability and death, particularly in low and .

Metformin is usually given to patients with diabetes to help control blood sugar levels, but preliminary studies suggest it could also be a potential treatment for pre-eclampsia.

So researchers in Australia and South Africa set out to evaluate whether extended release metformin could be used to prolong gestation in women diagnosed with preterm pre-eclampsia.

The trial took place at a large hospital in Cape Town, South Africa and involved 180 undergoing close monitoring (expectant management) for preterm pre-eclampsia.

Women were recruited between February 2018 and March 2020 when they were, on average, 29 weeks’ pregnant. None of them had diabetes or were currently using metformin or any other drugs that might interact with it.

Women were randomly split into two groups (arms): 90 received extended release metformin and 90 received placebo daily, until delivery.

The average time from randomisation to delivery was 17.7 days in the metformin arm and 10.1 days in the placebo arm, an average difference of 7.6 days. However, this difference was not statistically significant.

Two more analyses were carried out. The first (in women who continued to take metformin at any dose) showed an average 9.6 day longer gestation, and the second (in women who took the full dose of metformin) showed an average 11.5 day longer gestation. Both these results were statistically significant.

There were no differences between the two arms in terms of serious birth complications or death among both mothers and babies. And no serious adverse events were observed, although diarrhoea was more common in the metformin arm.

This is a robust and well designed trial, but the researchers acknowledge some limitations. For example, this was a single centre study where the women had a high incidence of HIV, obesity, and chronic hypertension, so the results may not be more widely applicable.

Further trials of metformin should be considered to confirm whether the drug can statistically significantly prolong gestation and to evaluate the benefits to newborns, they say. However, based on the findings of this study, “we are cautiously optimistic that extended release prolongs gestation in with preterm pre-eclampsia.”

More information: Use of metformin to prolong gestation in preterm pre-eclampsia: randomised, double blind, placebo controlled trial, BMJ (2021). DOI: 10.1136/bmj.n2103 , www.bmj.com/content/374/bmj.n2103

Citation: Diabetes drug may help to prolong preterm pregnancies in women with pre-eclampsia (2021, September 22) retrieved 5 October 2021 from https://medicalxpress.com/news/2021-09-diabetes-drug-prolong-preterm-pregnancies.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
South Australia's CALHN rolls out smart staff scheduling solution thumbnail

South Australia’s CALHN rolls out smart staff scheduling solution

The Central Adelaide Local Health Network in South Australia has deployed Core Schedule's smart staff rostering and scheduling platform across 15 services. Core Schedule streamlines the rostering and scheduling process for hospitals and healthcare facilities. Its installation is being tailored to suit a client’s hospital department, area, and team.   WHY IT MATTERS Taking note of…
Read More
AOC: ‘So Many People in This Country Hate Women’ thumbnail

AOC: ‘So Many People in This Country Hate Women’

Alexandria Ocasio-Cortez spoke about the impacts of misogyny in America, from her personal experience with sexual assault to the reversal of Roe v. Wade, in a new interview with GQ. The 32-year-old congresswoman, known as AOC, also reflected on the January 6 riot and the power of protest—and how all of this has shaped her
Read More
Leicester’s KAV Heading Home to O2 Academy thumbnail

Leicester’s KAV Heading Home to O2 Academy

Former Happy Mondays guitarist KAV is heading to Leicester later this month, bringing his sensational new solo material to the city’s premier music venue. Leicester-born KAV has been working on solo work for the past four years in Los Angeles, with his first single ‘Blaggers N’ Liars’ showcasing an incredible sound that has been compared…
Read More
Bright Health's financial troubles spread to Tennessee thumbnail

Bright Health’s financial troubles spread to Tennessee

Skip to main content Bright Health Group can add Tennessee to the growing list of states concerned about its ability to meet its financial obligations. Tennessee regulators placed the struggling health insurance company under supervision in November, according to Tennessee Department of Commerce and Insurance filings. Bright Health has been prohibited from spending more than
Read More
Index Of News
Consider making some contribution to keep us going. We are donation based team who works to bring the best content to the readers. Every donation matters.
Donate Now

Subscription Form

Liking our Index Of News so far? Would you like to subscribe to receive news updates daily?